Why It Matters

The Anti-Phosphatidylserine / Prothrombin Antibodies Panel evaluates advanced autoimmune clotting markers associated with thrombotic risk and Antiphospholipid Syndrome (APS). These antibodies may be present in patients with clinical signs of APS despite negative results on standard antiphospholipid testing, providing additional diagnostic sensitivity for identifying autoimmune-related clotting disorders.

Who Should Get It

Recommended for individuals with unexplained blood clots, recurrent pregnancy loss, suspected APS with negative conventional antibody testing, autoimmune-related thrombosis, or persistent clinical symptoms suggestive of clotting abnormalities.

How This Panel Is Used

Physicians use this panel to investigate autoimmune thrombotic risk, support diagnosis of seronegative APS, evaluate unexplained clotting events, and provide additional confirmation when standard APS testing is inconclusive. It is commonly ordered during hematologic, rheumatologic, and thrombosis evaluations.

What’s Included

This panel includes antibodies associated with autoimmune-mediated clotting activity and phospholipid-related thrombotic risk, supporting expanded evaluation of Antiphospholipid Syndrome and related autoimmune coagulation disorders.

aPS/PT IgG (Anti-Phosphatidylserine-Prothrombin Antibody IgG)

This test detects IgG antibodies against the phosphatidylserine–prothrombin complex, which are associated with abnormal blood clotting and autoimmune activity.

Diagnostic Value: The presence of aPS/PT IgG antibodies supports the diagnosis of Antiphospholipid Syndrome (APS), particularly in patients with unexplained thrombosis or recurrent pregnancy loss.

Clinical Significance: These antibodies can promote hypercoagulability by interfering with natural anticoagulant pathways. Measuring aPS/PT IgG enhances diagnostic sensitivity in patients who are negative for conventional antiphospholipid markers (such as lupus anticoagulant or anticardiolipin antibodies).

Symptom Correlation: Patients may experience deep vein thrombosis, stroke, miscarriages, or chronic headaches linked to vascular inflammation.

Because of its strong association with autoimmune-mediated clotting disorders, the aPS/PT IgG test provides valuable diagnostic and prognostic insight into antiphospholipid conditions.

aPS/PT IgM (Anti-Phosphatidylserine-Prothrombin Antibody IgM)

This test measures IgM antibodies against the phosphatidylserine–prothrombin complex, complementing the IgG subtype in evaluating autoimmune clotting risk.

Diagnostic Value: Elevated aPS/PT IgM levels indicate an early or transient immune response in Antiphospholipid Syndrome and related hypercoagulable states.

Clinical Significance: Testing both IgG and IgM subtypes improves detection accuracy and helps monitor disease activity or treatment response.

Symptom Correlation: Patients may present with leg swelling, shortness of breath, pregnancy complications, or neurological symptoms associated with clot formation.

Because it identifies an additional antibody class involved in coagulation disorders, aPS/PT IgM testing enhances the sensitivity of antiphospholipid evaluations.